Vitae Pharmaceuticals Inc (VTAE) Lifted to Outperf
Post# of 22755
Posted On: 03/22/2016 8:50:32 AM
Vitae Pharmaceuticals Inc (VTAE) Lifted to Outperform at JMP Securities
Posted by Lindsay Hyde on Mar 22nd, 2016 // No Comments
Vitae Pharmaceuticals Inc logoJMP Securities upgraded shares of Vitae Pharmaceuticals Inc (NASDAQ:VTAE) from a market perform rating to an outperform rating in a report published on Thursday morning, The Fly reports.
Vitae Pharmaceuticals (NASDAQ:VTAE) opened at 7.31 on Thursday. The firm’s market capitalization is $159.87 million. Vitae Pharmaceuticals has a 12-month low of $4.08 and a 12-month high of $18.71. The stock has a 50 day moving average of $7.74 and a 200 day moving average of $12.04.
Vitae Pharmaceuticals (NASDAQ:VTAE) last posted its earnings results on Thursday, March 3rd. The company reported ($0.52) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.62) by $0.10. The business earned $0.09 million during the quarter, compared to analyst estimates of $0.14 million. During the same quarter last year, the firm earned ($0.40) earnings per share. Vitae Pharmaceuticals’s revenue was down 42.9% compared to the same quarter last year. Equities research analysts anticipate that Vitae Pharmaceuticals will post ($2.23) earnings per share for the current year.
A number of other analysts have also recently issued reports on the stock. Stifel Nicolaus upgraded shares of Vitae Pharmaceuticals from a hold rating to a buy rating and set a $15.00 target price for the company in a research note on Thursday, March 17th. Zacks Investment Research upgraded shares of Vitae Pharmaceuticals from a sell rating to a hold rating in a research note on Saturday, March 5th. Wedbush reiterated an outperform rating and issued a $20.00 target price on shares of Vitae Pharmaceuticals in a research note on Thursday, March 3rd. Piper Jaffray reiterated a buy rating and issued a $23.00 target price (up from $18.00) on shares of Vitae Pharmaceuticals in a research note on Monday, January 4th. Finally, Wells Fargo started coverage on shares of Vitae Pharmaceuticals in a research note on Thursday, December 3rd. They issued an outperform rating for the company. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. The stock currently has an average rating of Buy and an average price target of $20.00.
In related news, Director Donald J. Hayden, Jr. sold 16,130 shares of the company’s stock in a transaction on Tuesday, December 29th. The shares were sold at an average price of $18.00, for a total transaction of $290,340.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Jeffrey S. Hatfield sold 22,524 shares of the company’s stock in a transaction on Wednesday, December 23rd. The shares were sold at an average price of $17.00, for a total transaction of $382,908.00. Following the transaction, the chief executive officer now owns 293,897 shares of the company’s stock, valued at $4,996,249. The disclosure for this sale can be found here.
A number of institutional investors recently added to or reduced their stakes in the stock. Candriam Luxembourg S.C.A. bought a new position in Vitae Pharmaceuticals during the fourth quarter valued at approximately $2,407,000. Dimensional Fund Advisors LP bought a new position in Vitae Pharmaceuticals during the fourth quarter valued at approximately $1,332,000. Driehaus Capital Management LLC bought a new position in Vitae Pharmaceuticals during the fourth quarter valued at approximately $4,397,000. DAFNA Capital Management LLC boosted its position in Vitae Pharmaceuticals by 172.6% in the fourth quarter. DAFNA Capital Management LLC now owns 193,224 shares of the company’s stock valued at $3,497,000 after buying an additional 122,339 shares during the last quarter. Finally, Balyasny Asset Management LLC bought a new position in Vitae Pharmaceuticals during the fourth quarter valued at approximately $2,096,000.
Vitae Pharmaceuticals, Inc is a clinical stage biotechnology company focused on discovering and developing small molecule drugs for diseases where there are unmet medical needs. The Company is developing a portfolio of product candidates generated by Contour, its structure-based drug discovery platform.
Posted by Lindsay Hyde on Mar 22nd, 2016 // No Comments
Vitae Pharmaceuticals Inc logoJMP Securities upgraded shares of Vitae Pharmaceuticals Inc (NASDAQ:VTAE) from a market perform rating to an outperform rating in a report published on Thursday morning, The Fly reports.
Vitae Pharmaceuticals (NASDAQ:VTAE) opened at 7.31 on Thursday. The firm’s market capitalization is $159.87 million. Vitae Pharmaceuticals has a 12-month low of $4.08 and a 12-month high of $18.71. The stock has a 50 day moving average of $7.74 and a 200 day moving average of $12.04.
Vitae Pharmaceuticals (NASDAQ:VTAE) last posted its earnings results on Thursday, March 3rd. The company reported ($0.52) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.62) by $0.10. The business earned $0.09 million during the quarter, compared to analyst estimates of $0.14 million. During the same quarter last year, the firm earned ($0.40) earnings per share. Vitae Pharmaceuticals’s revenue was down 42.9% compared to the same quarter last year. Equities research analysts anticipate that Vitae Pharmaceuticals will post ($2.23) earnings per share for the current year.
A number of other analysts have also recently issued reports on the stock. Stifel Nicolaus upgraded shares of Vitae Pharmaceuticals from a hold rating to a buy rating and set a $15.00 target price for the company in a research note on Thursday, March 17th. Zacks Investment Research upgraded shares of Vitae Pharmaceuticals from a sell rating to a hold rating in a research note on Saturday, March 5th. Wedbush reiterated an outperform rating and issued a $20.00 target price on shares of Vitae Pharmaceuticals in a research note on Thursday, March 3rd. Piper Jaffray reiterated a buy rating and issued a $23.00 target price (up from $18.00) on shares of Vitae Pharmaceuticals in a research note on Monday, January 4th. Finally, Wells Fargo started coverage on shares of Vitae Pharmaceuticals in a research note on Thursday, December 3rd. They issued an outperform rating for the company. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. The stock currently has an average rating of Buy and an average price target of $20.00.
In related news, Director Donald J. Hayden, Jr. sold 16,130 shares of the company’s stock in a transaction on Tuesday, December 29th. The shares were sold at an average price of $18.00, for a total transaction of $290,340.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Jeffrey S. Hatfield sold 22,524 shares of the company’s stock in a transaction on Wednesday, December 23rd. The shares were sold at an average price of $17.00, for a total transaction of $382,908.00. Following the transaction, the chief executive officer now owns 293,897 shares of the company’s stock, valued at $4,996,249. The disclosure for this sale can be found here.
A number of institutional investors recently added to or reduced their stakes in the stock. Candriam Luxembourg S.C.A. bought a new position in Vitae Pharmaceuticals during the fourth quarter valued at approximately $2,407,000. Dimensional Fund Advisors LP bought a new position in Vitae Pharmaceuticals during the fourth quarter valued at approximately $1,332,000. Driehaus Capital Management LLC bought a new position in Vitae Pharmaceuticals during the fourth quarter valued at approximately $4,397,000. DAFNA Capital Management LLC boosted its position in Vitae Pharmaceuticals by 172.6% in the fourth quarter. DAFNA Capital Management LLC now owns 193,224 shares of the company’s stock valued at $3,497,000 after buying an additional 122,339 shares during the last quarter. Finally, Balyasny Asset Management LLC bought a new position in Vitae Pharmaceuticals during the fourth quarter valued at approximately $2,096,000.
Vitae Pharmaceuticals, Inc is a clinical stage biotechnology company focused on discovering and developing small molecule drugs for diseases where there are unmet medical needs. The Company is developing a portfolio of product candidates generated by Contour, its structure-based drug discovery platform.
(0)
(0)
I'm in it to win it!
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
Scroll down for more posts ▼